Option chain shows key data for SAG Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for SAG Holdings.

SAG Holdings (NASDAQ:SAG) Stock, Option Chain

SAG Holdings

SAG Holdings Ltd engages in the business of distributing automotive and industrial spare parts with operations primarily based in Singapore, and global sales primarily generated from the Middle East and Malaysia. Its business is comprised of On-Highway Business serving the automotive sector and Off-Highway Business primarily servicing the marine, energy, mining, construction, agriculture, and oil and gas sectors. The On-Highway Business Segment supply genuine and aftermarket spare parts to customers through our Autozone retail outlets located in Singapore, as well as Malaysia. The Off-Highway Business Segment supply a wide range of components and spare parts for internal combustion engines with a strong focus on filtration products through Filtec.

SAG Holdings Ltd

Sagaliam Acquisition Corp

Saga - United States Dollar

SAGALIAM ACQUISITION CORP RT

Sagaliam Acquisition Corp Units (1 Ordinary Shares Class A & 1 Right)

SOUTH AMERICAN GOLD CORP by South American Gold Corp.

South American Gold Corp

Sage Therapeutics Inc

STERLING METALS CORP by Sterling Metals Corp.

Sterling Metals Corp

SAGA METALS CORP by Saga Metals Corp.

The Advisors' Inner Circle Fund III Strategas Global Policy Opportunities ETF

AB Sagax

SAGAX AB U/ADR by Sagax AB

WIIM

SRAD

Sportradar shares are trading higher after the company announced a multiyear agreement with MLB to provide sports performance analysis of prospects using its Synergy Coaching and Scouting solution.

Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) disclosed a contract from renewable energy company, RWE AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RWEOY#OTC">RWEOY</a>), to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42105671/rwe-to-harness-ai-driven-weather-modelling-with-hpe-private-cloud-ai" rel="noreferrer noopener">enhance weather data analysis</a>.
RWE has adopted HPE Private Cloud AI, part of the NVIDIA AI Computing by HPE portfolio, to streamline weather model data processing and enhance information retrieval with retrieval-augmented generation (RAG).
The on-premise solution allows RWE&#8217;s researchers to rapidly deploy private cloud AI infrastructure within policy frameworks, enabling quicker experimentation and scaling of AI projects across various domains and regions.
HPE Private Cloud AI, co-developed with NVIDIA and delivered via the HPE GreenLake cloud, offers RWE a streamlined platform for infrastructure management, process automation, and workload orchestration, including sustainability metrics.
This allows RWE&#8217;s research team to focus on model development, accelerating time-to-market and providing a competitive edge in the renewable energy sector.
Fidelma Russo, EVP &amp; GM, Hybrid Cloud &amp; CTO at HPE, said, &#8220;The ability to fine tune and inference AI-driven weather models will be a key enabler to unlock higher efficiencies for RWE&#8217;s renewable energy portfolio and will give them a significant competitive advantage in the market.&#8221;
&#8220;HPE Private Cloud AI is a unique turnkey solution that enables RWE&#8217;s researchers to reach the market quicker and handle massive datasets.&#8221;
Yesterday, Deloitte expanded its collaboration with HPE to implement the newly launched HPE Private Cloud AI with NVIDIA, enhancing its AI capabilities and accelerating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42085548/deloitte-and-hewlett-packard-enterprise-collaborate-to-deliver-private-cloud-ai-capabilities" rel="noreferrer noopener">deployment of Generative AI solutions</a>.
Investors can gain exposure to the stock via&nbsp;First Trust S&amp;P 500 Diversified Dividend Aristocrats ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNGZ#NASDAQ">KNGZ</a>) and Roundhill Generative AI &amp; Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHAT#NYSE">CHAT</a>).
Price Action: HPE shares are up 0.99% at $21.39 premarket at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42105704" target="_blank" rel="noreferrer noopener">SpaceX CEO Elon Musk Reveals Technical Glitch That Led Company To Drop Key Objective Of Starship&#8217;s 6th Test Flight</a></li>
</ul>

Equities

Large Cap

News

Contracts

CHAT

KNGZ

Rwe Ag Ord Bearer Dm5 American Depository Receipt

RWEOY

HPE Powers RWE's Renewable Energy with AI Weather Modeling

RBC Capital analyst Andrew Wong maintains NexGen Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NXE#TSX">NXE</a>) with a Outperform and raises the price target from C$10 to C$15.

Price Target

Analyst Ratings

TSX:NXE

RBC Capital Maintains Outperform on NexGen Energy, Raises Price Target to C$15

ROAD

Construction Partners shares are trading higher after the company raised its FY25 revenue guidance.

Addentax Group Corp. ("Addentax" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>), an integrated service provider focusing on garment manufacturing, logistics services, property management, and subleasing, has announced the signing of a Memorandum of Understanding (MOU) for nationwide strategic cooperation with Shenzhen Yingbin Brand Development Co., Ltd. ("Yingbin Brand"), a prominent brand management company headquartered in Guangdong.

ATXG

Addentax Group Corp. Announces Signing Of MOU For Strategic Cooperation With Shenzhen Yingbin Brand Development Co., Ltd., Offering A Wide Range Of Services In Brand Supply Chain Management, Product Supply Chain Solutions, And Marketing Supply Chain Strategies

Maximus shares are trading lower after the company on Wednesday reported worse-than-expected Q4 adjusted EPS results.

iQIYI shares are trading lower despite a Q3 earnings beat.

RBC Capital analyst Pammi Bir maintains Riocan REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/REI#TSX">REI</a>) with a Outperform and raises the price target from C$21 to C$22.

TSX:REI

TSX:REI/UN

RBC Capital Maintains Outperform on Riocan REIT, Raises Price Target to C$22

On Wednesday, Pyxis Oncology, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42099028/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical-phase-1-part-1-data" rel="noreferrer noopener">multiple solid tumors</a>.
Among evaluable Head and Neck Squamous Cell Carcinoma (HNSCC) patients treated at an identified dose range of PYX-201 from 3.6 – 5.4 mg/kg (n=6), a confirmed 50% objective response rate (ORR) was observed, including one confirmed complete response (CR) and two confirmed partial responses (PR).
The company additionally announced a Clinical Trial Collaboration Agreement with Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) for a Pyxis Oncology-sponsored study of PYX-201 in combination with Merck&#8217;s Keytruda (pembrolizumab) in patients with 1L and 2L HNSCC, HR+/HER2- breast cancer, and triple-negative breast cancer (TNBC) and sarcoma.
<ul>
<li>PYX-201 and Keytruda combination dose escalation and expansion study in 1L and 2L HNSCC with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the first half of 2026.</li>
</ul>
Exploratory PYX-201 Phase 1 monotherapy expansion cohorts are planned for ovarian cancer, NSCLC, HR+/HER2 breast cancer, TNBC, and sarcoma. Preliminary clinical data are expected in the second half of 2025.
<ul>
<li>The company also expects to initiate the PYX-201 and Keytruda combination study in HR+/HER2 breast cancer, TNBC, and sarcoma, with preliminary clinical data expected in the second half of 2025 and the first half of 2026.</li>
<li>Preclinical studies of PYX-201 combined with other agents in ovarian cancer and NSCLC will commence in 2025, followed by clinical studies with preliminary clinical data expected in 2026.</li>
</ul>
PYX-201 demonstrated favorable preliminary tolerability profile data with low incidence of dose discontinuation, interruptions, or delays due to treatment-related adverse events.
William Blair analysts note that PYX-201 shows limited effectiveness outside of head-and-neck cancer, with only 8.7% of patients (2 out of 23) responding to tolerable doses of 3.6 mg/kg, 4.4 mg/kg, and 5.4 mg/kg.
&#8220;At this point, we are unsure whether the three unconfirmed responses could ultimately be confirmed,&#8221; the analysts writes.
The analysts has reduced the probability of success for PYX-201 to 10% from 35%. The updated fair value stands at $250 million or roughly $4.25 per share, comprising $1.77 per share from PYX-201 and $2.48 per share of cash.
With no major stock-moving events expected until the second half of 2025, the analysts estimate the stock will trade around $2.80 per share soon. William Blair says it includes $1.77 per share for PYX-201 and $1.07 for remaining cash by late 2025.
William Blair downgrades <a target="_blank" href="https://www.benzinga.com/quote/PYXS/analyst-ratings" rel="noreferrer noopener">Pyxis to Market Perform</a>, saying, &#8220;Since we view the head-and-neck cancer results as difficult to differentiate, coupled with modest activity in other solid tumor histologies.&#8221;
Price Action: PYXS stock is down 42.15% to $2.21 during premarket trading on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42098028/qualcomms-shift-from-handsets-to-ai-and-automotive-wins-analysts-confidence" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s Shift From Handsets To AI And Automotive Wins Analysts&#8217; Confidence</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Biotech

Downgrades

Health Care

Movers

Trading Ideas

General

PYXS

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

SWVL

Swvl Signs Three-Year Contract With G4S In Saudi Arabia To Provide SaaS-Based Mobility Solutions, Enhancing Fleet Efficiency Across Riyadh, Jeddah, And Dammam With Over 14,000 Monthly Trips; Financial Terms Not Disclosed

NVDA

NVIDIA shares are trading higher following the company's Q3 earnings report.

Compass Point analyst Floris Van Dijkum upgrades Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from Neutral to Buy and maintains the price target from $17 to $17.

Upgrades

Compass Point Upgrades Pebblebrook Hotel to Buy, Maintains Price Target to $17

RBC Capital analyst Pammi Bir maintains SmartCentres REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SRU#TSX">SRU</a>) with a Outperform and raises the price target from C$27 to C$28.

TSX:SRU

TSX:SRU/UN

RBC Capital Maintains Outperform on SmartCentres REIT, Raises Price Target to C$28

As of Nov. 21, 2024, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Natural Gas Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>)</h3>
<ul>
<li>On Nov. 14, Natural Gas Services posted better-than-expected quarterly earnings. &#8220;We delivered another quarter of significant top and bottom-line growth, as well as a material increase in net cash provided by operating activities, as we further grow and optimize our business,&#8221; said Justin Jacobs, Chief Executive Officer. &#8220;Compression demand, particularly in the Permian Basin, remains robust. We continue to capitalize on our favorable industry position, innovative compression units, and strong customer relationships to increase investments in our large horsepower fleet as we look to drive growth in rental fleet horsepower, rental revenue, and cash flow.&#8221; The company's stock gained around 32% over the past month and has a <a href="https://www.benzinga.com/quote/NGS">52-week high of $26.00</a>.</li>
<li>RSI Value: 81.77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>NGS Price Action: Shares of Natural Gas Services closed at $25.91 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Range Resources Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>)</h3>
<ul>
<li>On Oct. 22, the company posted better-than-expected quarterly earnings. Dennis Degner, the Company&#8217;s CEO, commented, &#8220;This month marks the 20th anniversary of Range drilling the first commercial Marcellus shale well. The Marcellus and Utica now produce nearly one-third of U.S. natural gas, and the U.S. has become the leading global supplier of safe, clean, affordable natural gas. We are tremendously proud of the role Range has played in this hugely impactful achievement and we are even more excited about what the future holds as global energy demand increases, improving the quality of life for billions of people living in energy poverty.&#8221; The company's stock gained around 17% over the past month and has a <a href="https://www.benzinga.com/quote/RRC">52-week high</a> of $39.33.</li>
<li>RSI Value: 76.05</li>
<li>RRC Price Action: Shares of Range Resources closed at $35.16 on Wednesday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42094434/top-3-consumer-stocks-that-are-ticking-portfolio-bombs">Top 3 Consumer Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Top 2 Energy Stocks You May Want To Dump This Month

<ul>
<li>MSTR</li>
<li>NVDA</li>
<li>$BTC</li>
<li>CORN</li>
<li>MARA</li>
<li>COIN</li>
<li>SNOW</li>
<li>TSLA</li>
<li>AI</li>
<li>GLD</li>
</ul>
data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

$BTC

COIN

CORN

MARA

MSTR

SNOW

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 21, 2024 (Via Swaggy Stocks)

MULN

Mullen Automotive Prepares For Mid-2025 Launch Of US Battery Production, Expands Fullerton Facility With Additional High-Volume Battery Lines And Advanced R&D Capabilities To Support EV Innovation And Reduce Import Reliance

The 76,000-square-foot former Barnes &amp; Noble location has been empty for nearly two decades and is now under contract to Boston-based Hudson Group. According to the Boston Business Journal, citing sources familiar with the negotiations, the property is expected to sell for much less than its 2017 price tag of $63 million.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
Brown, who signed a record-breaking $303.7 million contract last year, planned to transform the five-story building into a hub for Black entrepreneurship. His vision included featuring Black-owned businesses on the street level and housing his startup accelerator program on the upper floors.
"A building is a core part of BostonXchange, so he's looking forward to finding a location," Malia Lazu, Brown's consultant on the initiative, told the Boston Business Journal. The search continues for an alternative site downtown or elsewhere in the city.
The report said that the NBA All-Star&#8217;s interest represents exactly what civic leaders hope to see for vacant downtown properties in post-pandemic Boston. Michael Nichols, president of the Downtown Boston Business Improvement District, supported Brown&#8217;s mission. &#8220;We remain motivated to work with Jaylen and his team to find a space that can serve as the long-term epicenter for their mission-focused work,&#8221; Nichols said.
Trending: Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a>
The property&#8217;s troubled history extends beyond the pandemic. After Barnes &amp; Noble closed in 2006, it sat vacant until L3 Capital and LaSalle Investment Management purchased it in 2017. Despite millions in upgrades, COVID-19 derailed their plans, forcing them to surrender the building to lender Wells Fargo last year to avoid foreclosure, the report noted.
Hudson Group, the prospective buyer, brings experience in transforming downtown Boston properties. The firm has converted buildings in the Leather District into residential units and partnered with Brookfield on a 26-story apartment tower on the Greenway.
Brown&#8217;s initiative, Boston XChange, launched this summer and recently announced its first cohort of 10 businesses. While the Washington Street location didn&#8217;t work out, his broader mission to address Boston&#8217;s racial wealth gap through real estate and entrepreneurship continues.
The setback points to the ongoing challenges in major commercial <a href="https://www.benzinga.com/real-estate/24/11/41702735/millionaire-in-10-years-these-real-estate-markets-might-take-you-there">real estate</a> markets. Property values have declined sharply since the pandemic, creating obstacles and opportunities for innovative development projects. 
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100. </a></li>
</ul>

Real Estate

Jaylen Brown Takes A Shot At Downtown Boston Real Estate, Misses 399 Washington

<a href="https://www.globenewswire.com/Tracker?data=7hELYvsZhYCPCZZRxPvWFPXftOcrsR529q0BccXuyCnKPo0Eoy124Va-2XR6jPg5lSEgNiJULTo2kF8gqq3OLW235gewhBmVmSataxtiQbM=">Lumos Pharma, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUMO#NASDAQ">LUMO</a>), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the <a href="https://www.globenewswire.com/Tracker?data=-kAJIm6iG1WBmRNwtlOVPPgHy3ST-VsJJJCqcM0zmevXz4rvwqE_vbVEwzbB0Yxipc_8dAs0TjYvUeSrDSvuIW1xcKSmhX2xa30Lg9ZcyZdvPQSiFvddVnL1YLSjeHDdRhQveDSqhDFvgWqa3NWE2rtGqKIhcfw1H6pT03o2laVM2Ak_lblI1TGslGc_Lhdu">62nd Annual European Society for Paediatric Endocrinology Meeting</a>, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK.

LUMO

Lumos Pharma Presents Updated Phase 2 OraGrowtH Data Demonstrating Sustained Growth On Oral LUM-201 To 24 Months In PGHD And Correlation Of Growth To LUM-201's Unique Pulsatile Mechanism Of Action At ESPE 2024

BLEUU

Trading Halt: Halt status updated at 9:15:00 AM ET: Quotation Resumption: News and Resumption Times

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), the Chinese electric vehicle (EV) maker, is seeing its shares trade lower in premarket trading on Thursday.
Macquarie analyst Eugene Hsiao downgraded the company&#8217;s rating from Outperform to Neutral and slashed the price target <a target="_blank" href="https://www.benzinga.com/quote/NIO/analyst-ratings" rel="noreferrer noopener">from $6.60 to $4.80.</a>
The downgrade follows a mixed fiscal third-quarter earnings report, which revealed a slight decline in year-over-year<a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42084907/nio-q3-earnings-11-6-gain-in-vehicle-deliveries-margins-improve-issues-robust-q4-delivery-outlook" rel="noreferrer noopener"> revenue and continued losses.</a>
NIO posted a revenue of 18.67 billion yuan ($2.66 billion) for the quarter, marking a 2.1% decrease from the same period in the previous year but an increase of 7.0% from the prior quarter. However, analysts had expected slightly higher revenue of $2.70 billion for the period.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42107863/us-futures-head-lower-as-nvidia-reports-slowdown-in-quarterly-revenue-growth-expert-says-market-weakness-is-perfectly-normal-but-late-november-is-still-possible" rel="noreferrer noopener">US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is &#8216;Perfectly Normal,&#8217; But Late November Rally Is Still Possible</a>
Excluding share-based compensation expenses, NIO reported an adjusted loss per share of 2.14 yuan, or a 31-cent loss, which was an improvement compared to the 2.28 yuan loss in the same quarter last year. Nonetheless, the company continues to struggle with narrowing its losses, though this quarter&#8217;s loss was slightly better than the 2.21 yuan loss seen in the second quarter of 2024.
Despite the disappointing financials, NIO executives have been actively unveiling new strategic developments.
The company shared details about its third EV brand, Firefly, which will officially launch on December 21, ahead of its parent company&#8217;s annual NIO Day event, reported <a target="_blank" href="https://cnevpost.com/2024/11/20/nio-officially-unveils-3rd-brand-firefly/" rel="noreferrer noopener">CnEV </a>Post. Firefly&#8217;s first model is expected to enter deliveries in the first half of 2025, a move seen as an effort to expand NIO&#8217;s presence in the competitive EV market.
Looking ahead, NIO has set a guidance of 72,000 to 75,000 vehicle deliveries for the fourth quarter, which represents a<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> year-over-year increase of 43.9% to 49.9%</a>. The company also projects revenue for the fourth quarter in the range of $2.804 billion to $2.904 billion, a growth of 15.0% to 19.2% compared to the same period last year.
Despite these optimistic projections, NIO&#8217;s stock has been under significant pressure in 2024, having plunged more than 45% year-to-date.
Price Action: NIO shares are trading lower by 1.29% to $4.60 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly" target="_blank" rel="noreferrer noopener">Target Says Shoppers Wait For &#8216;Deals&#8217; A Day After Rival Walmart Credits Market Gains To Wealthy Households</a></li>
</ul>

Media

What's Going On With NIO Stock Thursday?

IPO Roundup: Guardian Pharmacy Services, BKV Corp and more

U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up

IPO Roundup: FrontView REIT, StandardAero and more

U.S. IPO Weekly Recap: Standard Aero Soars In 7-IPO Week, While Big Tech Names Join Pipeline

IPO Roundup: KinderCare Learnings, Moove and more

IPO Roundup: Ingram Micro Holdings, Peak Resources and more

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

Ingram Micro and its private equity owner, Platinum Equity, sold 18.6 million shares at $22 each as the technology distributor returned to public trading in a busy week for the IPO market.

Ingram Micro Returns To Trading In Busy Week

Shares of Invizyne Technologies gained as much as 13% following the company's $15M initial public offering on Wednesday. LATEST IPOS AND DIRECT LIS...

Opening Day: Invizyne Technologies jumps after IPO

Invizyne Technologies opened on Nov. 13 at $11.10. Shares gained as much as 13% following the company's $15 million initial public offering. Additionally, Alpha Cognition opened on Nov. 12 at $7.00.

Invizyne Technologies Jumps After IPO

ACOG

ACTHF

ADUR

AGII

ALDFU

APUS

ASPCU

BEAGU

BIOA

BOLD

BYLT

CBNA

CBRS

CGGJ

CHARU

CTNM

CUPR

CURX

DRDBU

FBGL

FBLA

FMFC

GRDN

GSRT

HSPT

HSPTU

HTLM

HUHU

INGM

IZTC

LBGJ

LGCY

LHAI

LOAR

MAMO

MNDR

MOOV

NAMI

NTCL

NTWOU

OACCU

OCACU

PACS

PTLE

ROLR

SARO

SEPN

SNYR

SNYRD

SUNH

TDACU

TLIH

TMGX

UBXG

WYHG

YYGH

ZBAO

ZYBT

Press Releases

SAG HOLDINGS LIMITED ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND LISTING ON THE NASDAQ CAPITAL MARKET

SAG HOLDINGS LIMITED ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING

FILTEC, AN SAG HOLDINGS COMPANY, COMPLETES THE IMPLEMENTATION OF AUTOMATION TECHNOLOGY ON ITS DISTRIBUTION CENTER

Comments

SAG Holdings

SAG Holdings (SAG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga